US Health Journal Praises Brazil for Playing Hard Against AIDS Drugs Makers

Efavirenz
Brazil has set an example to other developing countries by employing "creative measures" to successfully tackle its HIV/AIDS epidemic, says a new study published by Health Affairs.

The study commends the country's methods employed in significantly lowering AIDS-related death and illness, such as developing generic AIDS drugs in public factories and threatening to produce generic versions of patented medicines.

In 2000, to combat rising treatment costs, Brazil's health minister José Serra pressured pharmaceutical companies to reduce their prices by threatening to issue a compulsory license that would enable local production of generic versions of patented antiretrovirals.

The Trade-Related Aspects of Intellectual Property Rights Agreement allows a developing country to invoke a compulsory license if the nation's health is at risk, thus allowing the production of patented drugs without payment to the patent holder.

Despite initial protests from the United States, the move proved successful and several companies slashed their prices. Brazil also started producing generic copies of non-patented medicines in 2001.

Brazil issued its first compulsory license to import Efavirenz – the most commonly used HIV/AIDS drug in the country, made by Merck & Co – from India in 2007 and began producing the drug locally this year.

"Brazil's challenges to multinational pharmaceutical companies promoted transparency about the high cost of patented medicines in an era when companies did not publicly share their drug prices," aid Amy Nunn, co-author of the study and assistant professor of medicine at Brown University in the United States.

She said in a press release: "Before Brazil's efforts, as recently as the year 2000, most people living with HIV/AIDS in developing countries died without receiving treatment."

Brazil's experience is valuable for middle-income countries, who are increasingly relying on generic medicines, say the authors.

Graham Dutfield, professor of international governance at the University of Leeds, United Kingdom, says Brazil has set an excellent example for other countries.

"Brazil's drug policy has been absolutely correct, giving priority to the human right to health over private commercial interests, something all countries are required to do under international human rights law," he affirmed.

The authors' findings – based on interviews and analysis of Brazilian media – are published in the July/August edition of Health Affairs.

This article appeared originally in Science and Development Network – www.scidev.net.

Tags:

You May Also Like

Brazilian Consumers Have Never Been So Confident

Brazilian consumers’ confidence in the economy and their own personal finances is on the ...

Brazil Cabinet: The Fall of a Dreamer and a Doer

Following his resignation, Brazil’s former Education Minister Cristovam Buarque, claimed he had been isolated ...

Brazil’s Lula to Sign Accord on Biofuel During Finland Trip

Next week, Brazil and Finland should sign a memorandum of understanding (MoU) in the ...

Daguerreotype and the Birth of Photography in Brazil

Louis-Jacques Mandé Daguerre (1787-1851) was a French artist from whose name was coined the ...

Lula and Chavez Tie Economic Knots

Brazilian President Luiz Inácio Lula da Silva arrives today for a state visit to ...

LETTERS

They were practically unknown from people outside the jail system until they staged the ...

Brazil Cuts Key Interest to Record Low, But It’s Still World’s Highest

For the ninth time in a row in a process that started last September, ...

London and New York Are Next for this Brazilian Behavioral Research Firm

Conducting behavioral research and seeking innovative solutions for the corporate world. That is the ...

Iraq Has Plenty of Money and Wishes to Do Business with Brazil

The Kurdistan DBX Trade Show began Tuesday, November 11, in Suleimaniya, in Northern Iraq, ...

19 Countries in Brazil to Buy Her Shrimp

Entrepreneurs from 19 countries, including Spain, France, Italy, and England, are participating in the ...